33 results about "Bile salt hydrolase" patented technology

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

The invention discloses a method for extracting bilirubin, cholic acid and chenodeoxycholic acid from chicken bile. The method comprises the steps of pretreatment, chicken bile treatment, hydrolysis reduction, chromatographic separation and the like. The method comprises the following steps: slicing frozen chicken gallbladder, heating, unfreezing and melting to denature protein into solid, then cooling, performing three-phase centrifugal degreasing and deproteinization, and adding three enzymes including biliverdin reductase, coenzyme I and glucose dehydrogenase to reduce free biliverdin and combined biliverdin, so as to obtain the biliverdin-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase. The method comprises the following steps: adding cholic acid and chenodeoxycholic acid into a container, adding gluconic acid hydrolase and bile salt hydrolase to hydrolyze biliverdin and bile acid, adding trypsin to hydrolyze impure protein, performing chromatography by using macroporous silica gel, and separating bilirubin, cholic acid and chenodeoxycholic acid by using different molecular space structures to obtain high-purity bilirubin, cholic acid and chenodeoxycholic acid. The method has the advantages of simple process, few types of used solvents, low toxicity, and facilitation of environmental protection and industrial production.

The application discloses an animal bifidobacterium producing bile salt hydrolase and application thereof in neonatal jaundice, and belongs to the technical field of microorganisms. The animal bifidobacterium lactis WXM screened by the application has the effect of relieving neonatal jaundice, can significantly improve weight loss of a jaundice individual in an early life stage, improve abnormal increase of a bilirubin level in serum, improve liver damage, improve the level of an enzyme related to liver function, the expression level of a related inflammatory factor in the liver and the expression level of an enzyme UGT1A1 related to bilirubin metabolism, and has the effect of relieving neonatal jaundice. The strain of the application has high safety and has wide application value in the fields of food, functional food, health products, medicine and the like.

The invention discloses a strain of lactobacillus muricatum and application thereof.The lactobacillus muricatum SZH025 obtained through the method has an obvious inhibiting effect on acinetobacter baumannii, klebsiella pneumoniae and escherichia coli under the in-vitro condition and is suitable for preventing and treating intestinal infectious diseases or adjusting intestinal flora; the cholate hydrolase (BSH) activity is remarkable, bile acid metabolism is facilitated, cholesterol excretion is promoted, and the blood fat reducing and regulating effects are achieved. In addition, the strain shows good safety characteristics, has relatively strong gastrointestinal tract environmental adaptability, has certain antioxidant function and ethanol decomposition capacity, is beneficial to alcohol metabolism, can produce oleic acid, and has potential probiotic effects of regulating lipid, resisting inflammation and improving the metabolic state of a host.

The invention discloses a probiotic with the characteristic of high yield of bile salt hydrolase and application of the probiotic in a preparation for preventing or improving cholestatic jaundice, and is characterized in that the probiotic is at least one of a bifidobacterium longum subsp. Infantis QS033 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35879 and a lactobacillus delbrueckii subsp. Lactis QS021 strain with the preservation number of CGMCC No.35880; according to the present invention, the Chukrasone A has the application of the Chukrasone A in the preparation of the product for preventing, relieving or regulating the cholestatic jaundice, and has the advantages of effective degradation of sodium glycocholate, sodium glycodeoxycholate, sodium glycochenodeoxycholate and sodium glycoursodeoxycholate, effective regulation of bile acid metabolism disorder in the cholestatic jaundice, and improvement of the cholestatic jaundice.

The invention discloses an airlift reactor for continuous fermentation production of bile salt hydrolase, and belongs to the technical field of biological fermentation equipment. The invention discloses an airlift reactor for continuous fermentation production of bile salt hydrolase. The top of the tank body is provided with a tank cover, the tank cover is provided with a feed port, the center of the inner wall of the bottom of the tank body is provided with turbulent flow columns which are uniformly distributed, and the tops of the turbulent flow columns are fixedly connected with a positioning ring; the gas distributor is mounted at the bottom of the tank body and is used for introducing dispersed gas into the tank body so as to accelerate uniform mixing of the reaction raw materials; the magnetic coupling stirring mechanism comprises a first driving assembly installed at the bottom of the tank body, through the optimal design of an adjustable inverted-cone-shaped dynamic diffusion assembly, the substrate diffusion range and mixing uniformity are remarkably improved, substrate deposition is effectively reduced, meanwhile, key components have excellent durability and sealing performance, and the service life of the device is prolonged. Therefore, the substrate utilization rate and the production efficiency of fermentation of the bile salt hydrolase are improved.

The present invention belongs to the field of microorganisms, and specifically relates to a plant lactobacillus and an application thereof. The plant lactobacillus is deposited in the Guangdong Microbial Culture Collection Center, and the deposit number is GDMCC No: 63911. The plant lactobacillus is used to ferment cattle bile, and a large amount of bile salt hydrolase is produced during the fermentation process, which can convert the bound bile acid in the cattle bile into free bile acid, and a high conversion rate can be achieved within 2-3 days, and the utilization value is high.

Compositions and methods of treating or preventing a reproductive disease or condition in a mammalian subject comprising administering to a mammalian subject in need thereof an effective amount of a substantially homogeneous and transformed population of enteric bacterial cells, wherein the administered bacterial cells have been engineered to express bile salt hydrolase (BSH). Compositions and methods for treating or preventing polycystic ovary syndrome (PCOS).

Disclosed are modified Cristinia parvata bile salt hydrolase (BSH) enzymes, prebiotics comprising the same, engineered bacterial cells comprising the modified BSH enzymes, probiotics comprising the engineered bacterial cells, methods of treating diseases and conditions using compositions comprising the modified enzymes, and food products.

Described herein are methods and compositions relating to inhibition of bile salt hydrolase (BSH) and uses thereof. Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (e.g., gastrointestinal infections; inflammatory bowel disease (IBD); appendicitis; crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; a liver disease (e.g., non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis), gastroesophageal reflux disease (GERD); celiac disease; diverticulosis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; intestinal leakage; the present invention relates to a method for treating a cancer (e.g., digestive cancer, liver cancer), a cancer (e.g., digestive cancer, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis). The method comprises administering to the subject a compound of Formula (I)-(XVIII).

Described herein are methods and compositions related to inhibiting bile salt hydrolase (BSH) and uses thereof. Provided herein is a method for treating a metabolic disorder (e.g., diabetes, obesity), gastrointestinal disease (e.g., a gastrointestinal infection; inflammatory bowel disease (IBD); appendicitis; Crohn's disease (CD); ulcerative colitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetes; hepatitis; liver diseases (e.g., Non-alcoholic Fatty Liver Disease (NAFLD); non-alcoholic steatohepatitis (NASH); hepatitis A; hepatitis B; hepatitis C; autoimmune hepatitis; and cirrhosis of the liver) gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcer; infectious colitis; irritable bowel syndrome; leaky gut; and cancer), cancer (e.g., cancer of the digestive system, liver cancer), or an inflammatory disease (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcer, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to a subject a compound of Formulae (I)-(XVIII).

Described herein are methods and compositions relating to the inhibition of bile salt hydrolase (BSH) and uses thereof.SOLUTION: Provided herein are methods for treating metabolic disorders (e.g., diabetes, obesity), gastrointestinal diseases (such as gastrointestinal infections; inflammatory bowel diseases (IBD); appendicitis; Crohn's disease (CD); ulcerative cholitis (UC); gastritis; enteritis; esophagitis; pancreatitis; diabetics; hepatits; hepatic diseases (such as non-alcoholic fatty liver disease (NAFLD); non-alcoholic fat hepatits (NASH); hepatits A; hepatits B; hepatits C; autoimmune hepatits; and cirrhosis of the liver); gastroesophageal reflux disease (GERD); celiac disease; diverticulitis; food intolerance; ulcers; infectious colitis; irritable bowel syndromes; intestinal wall leakage; and cancers); Methods for treating cancer (e.g., cancer of the digestive system, liver cancer) or inflammatory diseases (e.g., Crohn's disease, inflammatory bowel disease, ulcerative colitis, pancreatitis, hepatitis, appendicitis, gastritis, diverticulitis, celiac disease, food intolerance, enteritis, ulcers, gastroesophageal reflux disease (GERD), psoriatic arthritis, psoriasis, and rheumatoid arthritis) in a subject in need thereof comprising administering to the subject a compound represented by Formulae (I) - (XVIII).SELECTED DRAWING: None

Disclosed are modified Christensenella minuta bile salt hydrolase (BSH) enzymes, prebiotics comprising the same, engineered bacterial cells comprising the modified BSH enzymes, probiotics comprising the engineered bacterial cells, methods of using the compositions to treat diseases and disorders, comprising the modified enzymes, and food products.

The invention discloses a bile salt hydrolase as well as a preparation method and application thereof. The amino acid sequence of the bile salt hydrolase is shown as SEQ ID NO.2, and the nucleotide sequence of a gene for coding the bile salt hydrolase is shown as SEQ ID NO.1. The bile salt hydrolase has good acid resistance, the optimum pH value is 5.0, and after the bile salt hydrolase is treated for 1 h within the pH value range of 3.0-9.0, the residual enzyme activity is 80% or above; the optimum temperature is 40 DEG C, the strain can tolerate for 1 h under the conditions of 30 DEG C and 40 DEG C, and the residual enzyme activity is 60% or above. The recombinant strain E.coli / NCbsh3 is subjected to induced expression in a cholesterol-containing culture medium for 16 hours, and the cholesterol degradation rate reaches 56%.

The invention discloses a chicken bile acid extraction method which comprises the following steps: freezing chicken gall into blocks at low temperature, cutting the blocks into slices, putting the slices on a filter screen, unfreezing at room temperature, and collecting bile; carrying out enzyme deactivation treatment on bile, adjusting the pH value to 5.0-6.0, continuously adding bifidobacterium bifidum and ethyl acetate, stirring under a water bath condition until the pH value of a liquid mixture is stable and unchanged, and ending the reaction; standing and layering the obtained enzymatic hydrolysate, collecting an organic layer, carrying out rotary evaporation concentration on the organic layer, and drying to obtain the bile acid extract. The chicken bile acid is extracted by adopting a bile salt hydrolase one-pot method, and the method has the characteristics that the process steps are simple, the reaction conditions are mild and easy to control, and the operation is convenient; in addition, the extraction efficiency of bile acid and the product purity are improved under the assistance of an organic reagent, meanwhile, the problem of environmental pollution caused by strong acid and strong alkali is solved, and the green process requirement is met.

The application discloses a chemiluminescent probe for detecting bile salt hydrolase, a preparation method and application thereof, and belongs to the technical field of biological medicines.The structural formula of the chemiluminescent probe is shown as formula (I). The chemiluminescent probe can be selectively hydrolyzed by the bile salt hydrolase, and has high specificity and sensitivity. The probe can be used for in-vitro high-throughput screening of the BSH enzyme activity, and can also be applied to rapid detection of the BSH activity in complex biological samples (such as fecal samples), thereby providing a molecular tool for studying the mechanism of intestinal microbial bile acid metabolism and related metabolic diseases (such as obesity, diabetes, colorectal cancer and the like) and diagnosis.

This invention discloses the application of red ginseng polysaccharide in the preparation of pharmaceutical compositions for the prevention and treatment of inflammatory bowel disease, belonging to the field of medical formulation technology. It is the first to clearly demonstrate that red ginseng polysaccharide promotes the expression of bile salt hydrolase and 7α-hydroxysteroid dehydrogenase by targeting and upregulating the relative abundance of Bacteroides acidophilus and Clostridium lysate in the intestine, thereby driving the production of 7-ketolithocholic acid in the intestine. Through the TGR5 activation mediated by 7-ketolithocholic acid, it improves intestinal damage caused by inflammatory bowel disease, providing a solid experimental basis and theoretical support for the application of red ginseng polysaccharide in the preparation of drugs or functional foods for the prevention and treatment of inflammatory bowel disease.

The invention provides a preparation method of a prebiotic functional wall material prepared based on a Maillard reaction. The preparation method comprises the following steps: dissolving sodium caseinate and prebiotic oligosaccharide in water, carrying out a hydration reaction, adjusting the pH value, carrying out a Maillard reaction, and cooling in an ice bath to obtain a microcapsule wall material solution. The prepared microcapsule wall material is low in cost, simple in preparation method, high in grafting rate, strong in hydrophobicity and high in probiotic activity, and is beneficial to coating the lactic acid bacteria, improving the activity of the lactic acid bacteria and forming the microcapsule with a compact and stable structure; the lactic acid bacteria microcapsule prepared from the microcapsule wall material is compact and stable in structure, can effectively protect lactic acid bacteria, prevents the lactic acid bacteria from being in contact with external adverse conditions, improves the activity of the lactic acid bacteria in gastrointestinal fluid, heat, ions, pH and storage, and has relatively high embedding rate and load rate; the activity of the bile salt hydrolase in the gastrointestinal digestion process of the prepared lactic acid bacteria microcapsule for producing the bile salt hydrolase can be improved, and the reduction of the activity of the bile salt hydrolase is delayed.

The present invention provides a plant lactobacillus with high bile salt hydrolysis activity for improving obesity and its application. The Lactobacillus plantarum Lp20 is deposited with CCTCC No.M 2024381 and deposited on March 4, 2024. Its hydrolysis ability for GDCA is higher than that of the current control WCFS1 of Lactobacillus plantarum, reaching 91.62%. The genome bsh1 in Lactobacillus plantarum Lp20 is seamlessly knocked out, and the wild-type and mutant strains are intervened in the control of obese mice. It is found that only the wild-type Lp20 can significantly reduce weight gain, improve liver fatty degeneration and reduce blood lipid elevation, etc., directly indicating that BSH is the key material basis for Lactobacillus plantarum to reduce fat and reduce weight. Thereby providing an efficient method for studying the influence of strains on host metabolites, in particular, an effective method for verifying that Bsh1 alleviates obesity, eliminating the influence of the parent bacterial cell background, proposing the possibility of using the Lactobacillus plantarum bsh1 gene in regulating the bile salt hydrolysis activity of Lactobacillus plantarum, and clarifying the importance of bile salt hydrolase in weight management and blood lipid reduction.

Compositions and methods for treating Obstructive Sleep Apnea (OSA)-associated atherosclerosis comprising administering to a subject in need thereof an effective amount of a bile salt hydrolase (BSH) inhibitor such as caffeic acid phenethyl ester

The present application relates to: a composition for inhibiting bile salt hydrolase (BSH) comprising epicatechin as an active ingredient; a method for inhibiting bile salt hydrolase of an animal using same; and a use of catechin for inhibiting bile salt hydrolase.

Modified Christensenella minuta bile salt hydrolase (BSH) enzyme, prebiotics containing the same, engineered bacterial cells containing the modified BSH enzyme, probiotics containing engineered bacterial cells, methods of using compositions containing the modified enzyme for treating diseases and disorders, and foods are disclosed.

The invention discloses a preparation method of combined bile acid for feed, and the method comprises the following steps: S1, providing a catalyst which is whole cells of clostridium perfringens or bile salt hydrolase extracted from the whole cells of clostridium perfringens; s2, constructing a reaction system, and adding a bile acid substrate, an amino acid substrate and the catalyst into a buffer system with the pH value of 5.0-5.6; s3, under an anaerobic or micro-aerobic condition, carrying out a catalytic reaction at 35-40 DEG C to obtain a reaction solution containing the bound bile acid; and S4, carrying out post-treatment on the reaction liquid to obtain the combined bile acid product for the feed. Whole cells of clostridium perfringens or bile salt hydrolase (BSH / T) extracted from the clostridium perfringens are adopted as a catalyst, the catalyst has high catalytic activity and specificity in an acidic buffer system with the pH value of 5.0-5.6, the binding reaction of bile acid and various non-glycine / taurine amino acids can be efficiently catalyzed, the reaction conditions are mild, strong acid, strong base or high temperature and high pressure are not needed, and the method is suitable for industrial production. The method is suitable for large-scale production.

The invention discloses application of bacteroides fragilis in preparation of a medicine for preventing and / or treating porcine intestinal coronavirus infection. The research finds that bacteroides fragilis hydrolyzes bound bile acid through bile salt hydrolase (BSH) to generate free bile acid (such as lithocholic acid LCA and deoxycholic acid DCA), so that an antiviral effect is generated. The bacteroides fragilis can regulate bile acid metabolism through BSH enzyme activity to inhibit virus infection, which indicates that the bacteroides fragilis can be used for preventing or treating porcine intestinal coronavirus infection.

The invention relates to a genetically engineered bacterium for treating inflammatory bowel disease and application thereof, and belongs to the technical field of biological medicine. Specifically, escherichia coli Nissle 1917 (Escherichia coli Nissle 1917, ECN) is taken as a chassis microorganism, and a therapeutic engineering strain is constructed through a multi-stage gene editing strategy: firstly, bile salt tolerance related protein is screened through bioinformatics, and based on a CRISPR-Cas9 mediated homologous recombination technology, a screened homologous protein coding sequence is directionally integrated into a genome, and then a recombinant vector is constructed; therefore, the bile salt tolerance of the strain is improved; secondly, a bile salt hydrolase coding gene is integrated in a genome, and the inflammatory bowel disease is treated by regulating bile acid metabolism. The engineering bacterium effectively treats inflammatory bowel diseases through a dual action mechanism of enhancing intestinal colonization ability and regulating bile acid metabolism.

A composition having the following structure:wherein: R1 is OH, ester group, ether group, amine, thiol, thioether, halide, or a group containing an alkynyl or azido functionality; R2 is H, OH, ester group, ether group, amine, thiol, thioether, halide, or a group containing an alkynyl or azido functionality; R3 is a group containing a reactive functionality capable of covalent binding to a thiol or amine; and R4 is H, OH, ester group, ether group, amine, thiol, thioether, halide, or a group containing an alkynyl or azido functionality; wherein one of R1, R2 and R4 is a group containing an alkynyl or azido functionality. Also disclosed is a method for profiling changes in BSH enzyme activity by attaching active BSH enzymes in a sample to the probe shown above, attaching a tag to the probe, and detecting the active BSH enzymes to obtain an activity profile.

The present disclosure provides methods for treating colorectal cancer (CRC) or methods for reducing the risk of occurrence or delaying the occurrence of CRC in a subject by administering to the subject engineered native bacteria cells, wherein the engineered native bacteria cells are generated by transforming cultured population of native bacteria cells with one or more heterologous polynucleotides encoding bile salt hydrolase (BSH), and wherein the engineered native bacteria cells colonize in or on the subject and expresses BSH, thereby treating CRC or reducing the risk of occurrence or delaying the occurrence of CRC in the subject. Also described are populations of bacteria cells that are transformed with one or more heterologous polynucleotides encoding BSH, and compositions comprising such populations.

The invention discloses a plant lactobacillus WKLPP0041 strain with high BSH activity as well as a mutagenesis screening method and application of the plant lactobacillus WKLPP0041 strain, and belongs to the technical field of microorganisms. The plant lactobacillus WKLPP0041 is preserved in the China Center for Type Culture Collection on December 30, 2024, the preservation address is Wuhan, China, and the preservation number is CCTCC NO: M 20242958. According to the invention, gradient mutagenesis treatment is carried out on the screened plant lactobacillus WKLPP0040 with the BSH activity advantage through a physical mutagenesis-ultraviolet induction method, and a mutant strain, namely the plant lactobacillus WKLPP0041, of which the BSH activity is remarkably improved is obtained through screening. The BSH (bile salt hydrolase) activity and cholesterol degradation rate of the strain are remarkably improved, and the strain can improve blood fat, reduce inflammation and improve immunity.

The present application relates to: a feed composition or a feed additive, which comprise catechin and vitamin K; a method for inhibiting bile salt hydrolase (BSH) activity of an animal by using catechin and vitamin K or the feed composition comprising same; and a method for improving intestinal health of an animal.

The invention discloses a bile salt hydrolase BSH mutant protein and application thereof. The mutant protein is obtained by single mutation of an amino acid sequence of wild type bile salt hydrolase as shown in SEQ ID NO.1, and a single mutation site at least comprises any one of H91R, T122G, T122R, M161L, D166S, D167S, C189K, H215F, H215Y, K265P, G279A, A301R, Y305F or S314Q. Wild type bile salt hydrolase BSH from Bifidobacterium longum is used as a research object, an amino acid sequence of the wild type bile salt hydrolase BSH is designed and modified to obtain a series of mutant proteins with improved thermal stability and catalytic activity, and the thermal stability of the mutant proteins is 1.8-3.9 DEG C higher than that of the wild type bile salt hydrolase BSH. And moreover, the catalytic activity is improved by 1.1-4.3 times compared with that of a wild type, and the catalytic activity is obviously improved on the basis of keeping the stability of a protein structure. And a key mutation target set which can be directly used is provided for subsequent protein engineering modification of the bile salt hydrolase BSH.